R&D

European regulators have approved a new indication for Regeneron and Sanofi’s Praluent (alirocumab) to reduce cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).

Roche’s MabThera (rituximab) has been approved in Europe for the treatment of adults with moderate-to-severe pemphigus vulgaris (PV). PV is a...

A new collaboration agreement will see Iktos use its generative modelling AI technology to facilitate the rapid and cost-effective discovery and design of promising...